期刊文献+

胃癌组织与癌旁组织中ERCC1与AKT1的表达及临床意义 被引量:7

Expressions of ERCC1 and AKT1 in gastric cancer tissues and pericarcinoma tissues and their clinical significance
原文传递
导出
摘要 目的探讨胃癌组织中ERCC1与AKT1的表达及不同病理分期术后胃癌中ERCC1、AKT1表达与PFS的关系。方法用RT-PCR方法检测51例胃癌组织与癌旁组织的ERCC1与AKT1的表达,观察预后,并进行统计分析。结果胃癌组织中ERCC1、AKT1的阳性表达率分别为61%、71%,ERCC1、AKT1在癌旁组织中表达率高于癌组织,ERCC1、AKT1在淋巴结有无转移之间表达有统计学差异。ERCC1、AKT1阳性者Ⅰ期预后好于阴性者,在Ⅱ-Ⅳ期表达阳性者预后差。结论AKT1、ERCC1在癌旁组织中阳性表达率高于癌组织,ERCC1、AKT1在Ⅰ期胃癌术后表达阳性者预后好,而Ⅱ-Ⅳ期相反。 Objective To study expression of ERCC1 and AKT1 in gastric cancer tissues and to analyze the relationship between expression and PFS.Methods 51 cases of expressions of ERCC1 and AKT1 in gastric cancer tissues and adjacent normal tissues were detected by RT-PCR.The prognosis was observed and statistically analyzed.Result In 51 cases,the ERCC1(+) was 61% and AKT1(+) was 71%.The positive expressive rates of ERCC1 and AKT1 were higher in adjacent normal tissues than in gastric adenocarcinoma tissues.There was statistical difference in expressions of ERCC1 and AKT1 with or without lymph node metastasis.The prognosis of patients of ERCC1(+) and AKT1(+)was better in stage Ⅰ,while poor in stages Ⅰ-Ⅳ.Conclusion The positive expressive rates of ERCC1 and AKT1 in adjacent normal gastric cancer are higher than in gastric tissues.The prognosis of ERCC1(+) and AKT1(+) is better in stage Ⅰ,but poor in stages Ⅱ-Ⅳ.
出处 《山东大学学报(医学版)》 CAS 北大核心 2010年第3期86-89,101,共5页 Journal of Shandong University:Health Sciences
关键词 胃腺癌 基因 预后 Gastric adenocarcinoma Gene Prognosis
  • 相关文献

参考文献12

  • 1Azuma K, Komohara Y, Sasada T, et al. Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy[J].Cancer Sci, 2007, 98(9): 1336-1343.
  • 2Rosell R, Cuello M, Cecere F, et al. Usefulness of predictive tests for cancer treatment[J]. Bull Cancer, 2006, 93(8) :E101-E108.
  • 3Shinohara M, Chung Y J, Saji M, et al. AKT in thyroid tumorigenesis and progression [ J ]. Endocrinology, 2007, 148 ( 3 ) :942-947.
  • 4Nam S Y, Lee H S, Jung G A, et al. Akt/PKB activation in gastric carcinomas correlates with clinicopathologic variables and porgnosis I J]. APMIS, 2003, 111 (12) : 1105-1113.
  • 5Murakami D, Tsujitani S, Osaki T, et al. Experssion of phosphorylated Akt (pAkt) in gastric carcinoma predicts porgnosis and efficacy of chemotherapy[J].Gastric Cancer, 2007, 10( 1 ) :45-51.
  • 6Alex T, Merav Y L. Akt Signaling and cancer: surviving but not moving on[J]. Cancer Res, 2006, 66 (9) :3963- 3966.
  • 7Olaussen K A, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy [ J ]. N Engl J Med, 2006, 355 (10) :983-991.
  • 8Simon G R, Sharma S, Cantor A, et al. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer I J ]. Chest, 2005, 127 ( 3 ) : 978 -983.
  • 9Asselin E, Mills G B, Tsang B K. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin- induced apoptosis in human ovarian epithelial cancer cells [J]. Cancer Res, 2001, 61(5) :1862-1868.
  • 10Yang X, Fraser M, Moll U M, et al. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway[J]. Cancer Res, 2006, 66(6) :3126-3136.

同被引文献102

引证文献7

二级引证文献110

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部